Team Portfolio Raise Essays

F4/Vivo Capital/Activity

Vivo Capital Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

News

Marked its 30th anniversary by launching a new philanthropic initiative tied to healthcare innovation.

Vivo Capital 30th anniversary philanthropic initiative

vivocapital.comJUL 14, 2026

JUL 14, 2026

Vivo Capital | Activity | F4

Investment

Led Full-Life Technologies' $150M financing package for its global radiotherapeutics platform.

Full-Life Technologies

Full-Life Technologies Vivo Capital

full-life.comMAY 18, 2026

MAY 18, 2026

Exit

Portfolio company Ajax Therapeutics was acquired by Eli Lilly in a deal worth up to $2.3B.

Ajax Therapeutics

Ajax Therapeutics Vivo Capital

ajaxtherapeutics.comAPR 27, 2026

APR 27, 2026

Investment

Co-led Oricell Therapeutics' $110M pre-IPO financing round to accelerate global CAR-T development.

Oricell Therapeutics

Oricell Therapeutics Vivo Capital

oricell.comAPR 9, 2026

APR 9, 2026

Essay

Co-founders published a letter reflecting on the firm's 30-year history in healthcare investing.

A Letter From Our Co-Founders: Celebrating Vivo Capital's 30th Anniversary

vivocapital.comAPR 8, 2026

APR 8, 2026

4 exits· FEB 2026 – APR 2026Show all

Exit

Portfolio company Soleno Therapeutics was acquired by Neurocrine Biosciences for $2.9B.

Soleno Therapeutics

neurocrine.gcs-web.comAPR 6, 2026

APR 6, 2026

Exit

Portfolio company Terns Pharmaceuticals was acquired by Merck for $6.7B.

Terns Pharmaceuticals

Terns Pharmaceuticals Vivo Capital

ir.ternspharma.comMAR 25, 2026

MAR 25, 2026

Exit

Portfolio company Scientia Vascular was acquired by Medtronic for $550M.

Scientia Vascular

Scientia Vascular Vivo Capital

news.medtronic.comMAR 10, 2026

MAR 10, 2026

Exit

Portfolio company 35Pharma was acquired by GSK for $950M.

35Pharma

35pharma.comFEB 25, 2026

FEB 25, 2026

Investment

Participated in Kinaset Therapeutics' $103M oversubscribed Series B for an inhaled pan-JAK inhibitor in respiratory disease.

Kinaset Therapeutics

Kinaset Therapeutics Vivo Capital

businesswire.comJAN 10, 2026

JAN 10, 2026

New Fund

Closed its public equity fund with commitments of over $740 million.

Vivo Opportunity (public) fund close

businesswire.comMAY 7, 2025

MAY 7, 2025